Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2018.12.015
Abstract: PURPOSE We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit-risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS). METHODS Decision conferencing with clinical neurologists as… read more here.
Keywords: decision; risk; cladribine; patients rrms ... See more keywords
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2025 at "Neurology"
DOI: 10.1212/wnl.0000000000213967
Abstract: Background and Objectives The benefit of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) is believed to decrease with age. We aimed to compare disease outcomes with DMTs between patients with late-onset RRMS (LO-RRMS) and… read more here.
Keywords: age; disease; treatment; patients rrms ... See more keywords
Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.730342
Abstract: Background and Objectives Inhibition of de novo pyrimidine synthesis in proliferating T and B lymphocytes by teriflunomide, a pharmacological inhibitor of dihydroorotate dehydrogenase (DHODH), has been shown to be an effective therapy to treat patients… read more here.
Keywords: cd8; treatment; dhodh inhibition; patients rrms ... See more keywords